Download full-text PDF |
Source |
---|
Curr Oncol
October 2019
Schulich School of Medicine and Dentistry, London Regional Cancer Program, London, ON.
Gemcitabine is a chemotherapeutic agent used in a wide variety of solid tumours. Known side effects include a dose-limiting myelosuppressive toxicity, mild rash, and radiation-dependent dermatitis. Rarely, localized inflammation in the form of pseudocellulitis has also been observed.
View Article and Find Full Text PDFCutis
November 2018
Division of Hematology/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
SAGE Open Med Case Rep
October 2018
Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA.
Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus alopecia, and palmar-plantar erythrodysesthesia.
View Article and Find Full Text PDFJAAD Case Rep
July 2015
Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
J Oncol Pharm Pract
October 2015
Department of Internal Medicine, University of Connecticut Health Center, Farmington, CT, USA.
Pseudocellulitis has been previously described with the use of chemotherapy agent gemcitabine. This condition is thought to occur due to vascular toxicity and increased localized permeability of the skin capillaries. We report herein a case of recurrent pseudocellulitis due to gemcitabine in a patient with metastatic pancreatic cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!